Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.59 |
| ▸ | CCNK | O75909 | 4/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CCNH | P51946 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241004 | 1.00 | HCRTR2 (0.59) | HCRTR2HCRTR1CCNKCDK12CYP3A4 | |
| SCHEMBL18697564 | 0.78 | HCRTR2 (0.71) | HCRTR2HCRTR1CCNKCDK12MAPK8 | |
| SCHEMBL20144830 | 0.78 | HCRTR2 (0.71) | HCRTR2HCRTR1CCNKCDK12MAPK8 | |
| SCHEMBL1672215 | 0.78 | HCRTR1 (0.86) | HCRTR2HCRTR1 | |
| SCHEMBL3654286 | 0.76 | HCRTR2 (0.60) | HCRTR2HCRTR1CCNKCDK12KDM4E | |
| SCHEMBL4244142 | 0.76 | HCRTR2 (0.60) | HCRTR2HCRTR1CCNKCDK12KDM4E | |
| SCHEMBL8224292 | 0.75 | CDK7 (0.62) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL3652656 | 0.75 | HDAC8 (0.54) | CCNKCDK12CYP3A4MAPK8MAPK9 | |
| SCHEMBL3649511 | 0.75 | HDAC8 (0.54) | CCNKCDK12CYP3A4MAPK8MAPK9 | |
| SCHEMBL3649515 | 0.75 | HDAC8 (0.54) | CCNKCDK12CYP3A4MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | HCRTR2 2/4885HCRTR1 1/4885CCNK 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.